Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its newer products will offset the loss of revenue from patent expirations and ...